Metro Ogryzlo was born in 1915 in Dauphin, Manitoba. He graduated from the Faculty of Medicine at the University of Manitoba in 1938 and interned in Winnipeg. After serving in the Royal Canadian Air Force during the Second World War, Dr Ogryzlo took additional training in Internal Medicine and Rheumatology at the University of Toronto where he became Director of the Rheumatic Diseases Unit, Professor of Medicine and a pioneer in the field of rheumatology.

Dr. Ogryzlo’s professional life was dedicated to improving the care of patients with rheumatic diseases and it was his vision that helped establish the Arthritis Centres at Universities throughout Canada. One of his major accomplishments was the establishment of the Journal of Rheumatology, which has become one of the most widely read international journals in the rheumatology community.

Upon his death in 1977, Dr. Ogryzlo’s family set up a memorial fund in his memory which provides the Section of Rheumatology with the funding to annually invite distinguished professors to the University of Manitoba.
Dr. Paul R. Fortin

Dr. Fortin obtained his medical degree from ‘Université Laval’ in Quebec City and graduated from McGill University in Rheumatology. He obtained a Master’s in Public Health from Harvard University School of Public Health, followed by three years of special training in clinical epidemiology as a Harvard post-doctoral research fellow. He returned to McGill University and to the Montreal General Hospital/McGill University Health Centre and Research Institute between 1992 and 2000, where he was funded uninterruptedly by operating grants from The Arthritis Society (TAS) and/or the Canadian Institutes of Health Research (CIHR). In 2000 Dr. Fortin joined the staff of Toronto Western Division/University Health Network (UHN) and Research Institute as a Clinician Scientist and Director of Clinical Research for the Arthritis Centre of Excellence. He became Full Professor of Medicine at the University of Toronto in 2007 and held cross-appointments as staff at the Hospital for Sick Children and as Associate Professor at the Institute of Medical Sciences and the Department of Health Policy, Management and Evaluation of the University of Toronto. In August 2011, he moved to the Université Laval and Clinical Researcher at the ‘Centre de Recherche du CHU de Québec’ in Quebec City where he is actively building up research capacity in clinical rheumatology and a unique SARD research program.

Dr. Fortin has been working on a better understanding of the bio-psycho-social impact of chronic rheumatic diseases such as systemic lupus erythematosus (SLE), the antiphospholipid antibody syndrome (APS), systemic autoimmune rheumatic diseases (SARD), osteoarthritis and rheumatoid arthritis. He is particularly interested in developing interventions for the treatment of SLE, APS and SARD.

His methodological interests cover the development and validation of health status measures and other clinical tools such as measures of disease activity or damage in SLE. His other interests include the development of risk profiles for arterial or venous thrombosis in APS, the testing of treatments of disease activity or cardiovascular disease in SLE, or the validation of biological markers in lupus and SARD with a special focus on CIHR-funded work on the study of microparticles and mitochondria.

Dr Fortin received the Kirkland Scholar Award in 2007, and the prestigious Distinguished Senior Research Investigator Award from The Arthritis Society of Canada. In 2010, he received the Hope Award from the Lupus Ontario to recognize his outstanding leadership in improving the lives of people with lupus. In July 2012, he received a tier 1 Canada Research Chair in Systemic Autoimmune Rheumatic Diseases. In May 2015, he received the Jeffrey Shiroky Research Award for his accomplishments in clinical research in rheumatology.

Title: Lupus or the Imitation Game

Objectives:

- To learn new development in the research of bio markers in lupus and the possible role of microparticles.
- To discover how treating lupus is an emergency in slow-motion.
- To know how new treatments for lupus are becoming available for trials

Paul R. Fortin, MD, MPH, FRCPC

Professor of Medicine

Université Laval,

Clinical Researcher at the
‘Centre de Recherche du CHU de Québec’,

Canada Research Chair in Systemic Autoimmune Rheumatic Diseases